A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 13 Sep 2018 Planned number of patients changed from 35 to 40.
- 04 Apr 2017 New trial record
- 03 Apr 2017 Status changed from not yet recruiting to recruiting.